Breast Cancer Research and Treatment

, Volume 125, Issue 1, pp 65–72

Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy

  • Sylvain Ladoire
  • Laurent Arnould
  • Grégoire Mignot
  • Bruno Coudert
  • Cédric Rébé
  • Fanny Chalmin
  • Julie Vincent
  • Mélanie Bruchard
  • Bruno Chauffert
  • François Martin
  • Pierre Fumoleau
  • François Ghiringhelli
Preclinical study

DOI: 10.1007/s10549-010-0831-1

Cite this article as:
Ladoire, S., Arnould, L., Mignot, G. et al. Breast Cancer Res Treat (2011) 125: 65. doi:10.1007/s10549-010-0831-1

Abstract

The Forkhead Box Protein 3 is highly expressed not only in regulatory T cells, but also in tumor cells, acting as a transcriptional repressor of breast oncogenes including HER2. We investigated the prognostic significance of Foxp3 expression in cancer cells in a large cohort of patients with HER2-overexpressing breast carcinoma treated with neoadjuvant chemotherapy. Foxp3-positive tumor cells were detected by immunohistochemistry in 103 patients with primary invasive HER2-overexpressing breast carcinoma, and treated with neoadjuvant chemotherapy, with or without trastuzumab. Kaplan–Meier analysis and Cox regression model were used to assess relapse-free and overall survival, respectively, and according to the presence or the absence of Foxp3 expression in tumor cells. Breast cancer cells were Foxp3+ in 57% of tumors. Foxp3 expression in breast cancer cells was associated with better relapse-free (P = 0.005) and overall survival (P = 0.03). By multivariate analysis, the presence of Foxp3+ tumor cells produced an independent prognostic factor for both better relapse-free (P = 0.006) and overall survival (P = 0.03). These findings indicate that the presence of Foxp3+ tumor cells represents a new independent prognostic factor of improved outcome in HER2-overexpressing breast carcinoma, which could help identify high-risk patients for additional therapies after neoadjuvant chemotherapy.

Keywords

Foxp3HER2Breast cancerTumor cellsNeoadjuvant chemotherapy

Copyright information

© Springer Science+Business Media, LLC. 2010

Authors and Affiliations

  • Sylvain Ladoire
    • 1
    • 2
    • 3
  • Laurent Arnould
    • 3
  • Grégoire Mignot
    • 2
  • Bruno Coudert
    • 1
  • Cédric Rébé
    • 2
    • 3
  • Fanny Chalmin
    • 2
  • Julie Vincent
    • 2
  • Mélanie Bruchard
    • 2
  • Bruno Chauffert
    • 1
    • 2
  • François Martin
    • 2
  • Pierre Fumoleau
    • 1
  • François Ghiringhelli
    • 1
    • 2
    • 3
    • 4
  1. 1.Department of Medical OncologyCentre Regional de Lutte Contre le Cancer Georges François LeclercDijonFrance
  2. 2.Institut National de la Santé et de la Recherche MédicaleUniversity of DijonDijonFrance
  3. 3.Department of Pathology and Molecular BiologyCentre Regional de Lutte Contre le Cancer Georges François LeclercDijonFrance
  4. 4.Faculté de MédecineCentre Georges François Leclerc, Centre de Recherche INSERM 866DijonFrance